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Summary
Aims: To assess the safety and efficacy of omarigliptin in subjects with type 2 diabetes 
mellitus	(T2DM)	and	chronic	renal	impairment	(RI).
Methods: Patients	with	T2DM	with	moderate	RI	 (estimated	 glomerular	 filtration	 rate	
[eGFR]	≥30	to	<60	mL/min/1.73	m2)	 (N=114),	severe	RI	(eGFR	<30	mL/min/1.73	m2)	
(N=55)	or	end-	stage	renal	disease	on	dialysis	(N=44),	who	were	either	not	on	an	antihy-
perglycaemic	agent	therapy	for	at	least	12	weeks	at	screening,	washed-	off	of	oral	antihy-
perglycaemic	agent	monotherapy	or	 low-	dose	dual	combination	therapy,	or	on	 insulin	
monotherapy,	with	 baseline	 glycated	haemoglobin	 (HbA1c)	 of	 6.5%-	10.0%	were	 ran-
domised	to	omarigliptin	or	to	placebo	for	24	weeks	 (primary	end-	point)	followed	by	a	
30-	week	period	with	subjects	on	placebo	switched	to	blinded	glipizide	(if	not	on	insulin).
Results: After	 24	weeks,	 from	 a	mean	 baseline	HbA1c	 of	 8.4%	 in	 the	 omarigliptin	
group	and	8.3%	in	the	placebo	group,	the	least	squares	mean	(95%	CI)	change	from	
baseline	 in	HbA1c	 in	 the	overall	population	 (all	 renal	 strata	combined)	was	−0.77%	
(−1.00	to	−0.54)	in	the	omarigliptin	group	and	−0.44%	(−0.67	to	−0.21)	in	the	placebo	
group;	 between-	group	 difference	 of	 −0.33%	 (−0.63	 to	 −0.02);	 P=0.035.	 After	
24	weeks,	the	incidences	of	subjects	with	symptomatic	hypoglycaemia,	one	or	more	
adverse	 event	 (AE),	 drug-	related	AE,	 serious	AE	 and	 discontinuation	 due	 to	 an	AE	
were similar in the omarigliptin and placebo groups.
Conclusions: In	this	study	in	subjects	with	T2DM	and	RI,	relative	to	placebo,	omariglip-
tin	 provided	 clinically	 meaningful	 reductions	 in	 HbA1c,	 had	 a	 similar	 incidence	 of	
symptomatic hypoglycaemia and was generally well tolerated.
1  | INTRODUCTION
Among	 patients	 with	 type	 2	 diabetes	 mellitus	 (T2DM),	 the	 preva-
lence with renal impairment (defined as an estimated glomerular fil-
tration	 [eGFR]	 rate	 less	 than	 60	mL/min/1.73	m2)	 is	 approximately	
22%.1 Definitions of renal impairment that include the presence of 
albuminuria in addition to reduced eGFR yield estimates as high as 
35%.2	T2DM	is	a	leading	cause	of	kidney	failure	accounting	for	nearly	
44%	of	new	cases.3	Moreover,	having	both	T2DM	and	kidney	disease	
is	associated	with	 increased	mortality	compared	with	having	T2DM	
alone.4 Because of safety and tolerability issues, antihyperglycaemic 
treatment	 options	 for	 patients	with	 T2DM	who	 have	 chronic	 renal	
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impairment	(RI),	especially	those	with	an	eGFR	<45	mL/min/1.73	m2 
or	end-	stage	renal	disease	(ESRD)	on	dialysis,	is	more	restricted	than	
for	patients	with	T2DM	with	normal	renal	function	or	mild	RI,	despite	
recent recommendations that broaden the use of metformin in this 
population.5-7	 Over	 the	 past	 decade,	 dipeptidyl	 peptidase-	4	 (DPP-	
4)	 inhibitors	have	become	an	established	 therapy	 for	 the	 treatment	
T2DM8,9 and are among the treatment options available for patients 
with	T2DM	and	chronic	RI.5
Omarigliptin	(MK-	3102)	is	a	selective,	oral	DPP-	4	inhibitor	with	a	
half-	life	that	enables	once-	weekly	dosing	that	is	primarily	eliminated	
by	 renal	 excretion.10	 A	 once-	weekly	 oral	 antihyperglycaemic	 agent	
(AHA)	has	the	potential	to	provide	patients	with	T2DM	an	additional	
option	 for	 managing	 their	 glycaemic	 control	 as	 part	 of	 a	 patient-	
centred approach. Omarigliptin has previously been demonstrated to 
have	efficacy	comparable	to	sitagliptin,	a	marketed	daily	DPP-	4	inhib-
itor,11,12 and is approved in Japan.
Herein,	we	report	the	results	of	a	global,	double-	blind,	randomised,	
parallel-	group	Phase	3	clinical	 trial,	which	assessed	 the	efficacy	and	
safety	of	omarigliptin	administered	once-	weekly	(q.w.)	in	subjects	with	
moderate and severe RI and ESRD on dialysis.
2  | MATERIALS AND METHODS
2.1 | Subjects
Eligible	patients	for	the	study	were	male	or	female	≥30	years	of	age	
with	T2DM	and	moderate	RI	(eGFR	≥30	to	<60	mL/min/1.73	m2)	or	
severe	RI	(eGFR	<30	mL/min/1.73	m2),	as	determined	by	the	modi-
fication	of	diet	in	renal	disease	(MDRD)	formula,13 or ESRD on di-
alysis	for	at	least	6	months.	Eligible	patients	were	either	(1)	not	on	
an	AHA	(naïve	or	off	therapy	for	≥12	weeks)	with	glycated	haemo-
globin	(HbA1c)	≥7.0%	and	≤10.0%;	(2)	on	a	single	oral	AHA	or	low-	
dose	dual	oral	combination	AHA	(ie,	at	≤50%	of	maximum	labelled	
dose	of	each	agent)	with	an	HbA1c	of	≥6.5%	and	≤9.0%;	or	(3)	on	a	
stable	insulin	regimen,	at	a	dose	of	at	least	15	U/d,	for	≥10	weeks,	
with	no	oral	AHA	and	HbA1c	≥7.5%	and	≤10.0%	and	fasting	plasma	
glucose	 (FPG)	 >7.22	mmol/L.	 Subjects	 on	 oral	 AHA	 therapy	 had	
their	medication	discontinued	(“washed-	off”).	Subjects	had	a	fast-
ing	finger-	stick	glucose	>7.22	mmol/L	and	<14.43	mmol/L	at	ran-
domisation. Subjects who entered the trial on insulin monotherapy 
at screening were to remain on a stable dose of insulin throughout 
the remainder of the trial unless glycaemic rescue criteria were met 
(see	below).	A	stable	insulin	regimen	was	defined	as	all	daily	insulin	
doses	within	±10%	of	the	subject’s	usual	administered	daily	dose.	
Subjects	could	be	receiving	premixed,	intermediate-	acting	or	long-	
acting	 insulin	 (premeal	 short-	acting	 or	 rapid-	acting	 insulins	 were	
not	allowed).
Patients	were	excluded	from	the	study	if	they	had	type	1	diabetes,	
a	history	of	ketoacidosis,	a	C-	peptide	level	<0.7	ng/mL,	active	liver	dis-
ease, significant cardiovascular disease, a haematological disorder or a 
history of malignancy, or had been treated with any incretin mimetic 
or	 thiazolidinedione	within	 the	prior	12	weeks	of	 screening,	or	with	
omarigliptin at any time prior to signing informed consent.
Laboratory	 exclusion	 criteria	 included	 alanine	 aminotransferase	
(ALT)	or	aspartate	aminotransferase	(AST)	>2	times	the	upper	limit	of	
normal	 (ULN),	 triglycerides	 >600	mg/dL	 or	 thyroid-	stimulating	 hor-
mone outside the central laboratory normal range.
2.2 | Study design
This	was	a	randomised,	placebo-	controlled,	parallel-	group,	double-	blind,	
multicentre	study	(Figure	S1)	conducted	at	109	centres	in	Australia	(4),	
Canada	(3),	Croatia	(6),	Czech	Republic	(5),	Georgia	(6),	Hong	Kong	(5),	
Hungary	(6),	Israel	(4),	Malaysia	(9),	Philippines	(3),	Poland	(7),	Russia	(5),	
Serbia	 (3),	South	Africa	 (4),	Spain	 (8),	 the	United	Kingdom	(4)	and	the	
United	States	(27).	Study	duration	was	up	to	69	weeks,	 including	a	1-	
week	screening	period,	an	8-	week	“wash-	off”	period	(for	patients	on	oral	
AHA	at	screening),	a	2-	week	single-	blind	placebo	run-	in	period,	a	54-	
week	double-	blind	treatment	period	consisting	of	a	24-	week	placebo-	
controlled	 period	 (Phase	 A)	 and	 a	 30-	week	 active-	controlled	 period	
(Phase	B)	and	a	post-	trial	phone	follow-	up	28	days	after	final	dose.
Subjects were randomised to omarigliptin or matching placebo in a 
1:1 ratio. Randomisation was stratified based on renal status, medical 
history of cardiovascular disease or heart failure and treatment with 
insulin at screening. Subjects with moderate RI received omarigliptin 
25	mg	or	matching	placebo	q.w.	Subjects	with	severe	RI	or	with	ESRD	
on	dialysis	received	omarigliptin	12.5	mg	or	matching	placebo	q.w.
During	Phase	B,	 subjects	 receiving	placebo	during	Phase	A	con-
tinued to receive omarigliptin placebo; those who were not on insulin 
were treated with blinded glipizide at a starting dose of 2.5 mg once 
daily	and	electively	titrated,	based	on	glycaemic	control,	up	to	a	max-
imum of 20 mg/d. During Phase B, subjects receiving either omari-
gliptin	or	placebo	and	who	were	on	insulin	during	Phase	A	continued	
to receive omarigliptin or placebo and did not receive blinded glipizide/
glipizide-	matching	placebo.	Subjects	receiving	omarigliptin	who	were	
not	on	insulin	during	Phase	A	received	glipizide-	matching	placebo.
Subjects not meeting progressively stricter prespecified glycae-
mic	control	criteria	postrandomisation	were	rescued	 (see	Figure	S1).	
In	 Phase	 A,	 subjects	 not	 on	 insulin	 were	 rescued	 with	 open-	label	
What’s known
•	 Omarigliptin	is	a	once-weekly	DPP-4	inhibitor	that	is	pri-
marily	 eliminated	 by	 renal	 excretion,	 which	 has	 been	
demonstrated to have efficacy comparable to sitagliptin, 
a	daily	DPP-4	inhibitor.
What’s new
• This article presents the results of a trial conducted in 
subjects with type 2 diabetes with renal impairment that 
support the efficacy and safety of the 25 mg dose of 
omarigliptin in subjects with moderate renal impairment, 
and the 12.5 mg dose of omarigliptin in subjects with se-
vere	RI	and	end-stage	renal	disease	on	dialysis.
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glipizide,	while	subjects	on	insulin	were	rescued	by	up-	titrating	insu-
lin.	 In	Phase	B,	 subjects	on	open-	label	glipizide	or	blinded	glipizide/
glipizide-	matching	 placebo	who	 needed	 rescue	 after	 maximum	 up-	
titration	 of	 glipizide	 had	 open-	label	 glipizide	 or	 blinded	 glipizide/
glipizide-	matching	placebo	discontinued,	and	were	rescued	with	insu-
lin glargine. In Phase B, subjects on insulin who needed rescue had 
their	 insulin	 up-	titrated	 or	 insulin	 regimen	 changed.	 Randomisation	
was done centrally using an interactive voice response system.
The	study	(MK-	3102-	019,	NCT01698775)	was	conducted	in	accor-
dance with the principles of Good Clinical Practice and was approved 
by the appropriate institutional review boards and regulatory agencies.
2.3 | Study evaluations
The	primary	objectives	of	Phase	A	of	this	study	were	assessment	of	
the efficacy, safety and tolerability of omarigliptin compared with 
placebo	 through	 24	weeks	 of	 treatment.	 The	 primary	 study	 hy-
pothesis	was	that	24	weeks	of	treatment	with	omarigliptin	provides	
greater	 reduction	 from	baseline	 in	HbA1c	 than	 treatment	with	pla-
cebo.	Secondary	objectives	of	Phase	A	were	to	assess	the	effect	of	
omarigliptin compared with placebo on change from baseline FPG and 
eGFR	after	24	weeks	of	treatment.	The	objectives	of	Phase	B	were	to	
assess	the	effect	of	omarigliptin	on	change	from	baseline	of	HbA1c,	
FPG	and	eGFR	after	54	weeks	of	treatment.
2.4 | Efficacy end- points
Efficacy	end-	points	were	changes	 from	baseline	 in	HbA1c	and	FPG	
and	percentages	of	subjects	at	HbA1c	goal	of	<7.0%.
2.5 | Safety end- points
Safety	 assessment	 included	 collection	 of	 AEs,	 physical	 examination	
(including	vital	signs),	laboratory	blood	chemistry	(including	ALT,	AST,	
total	bilirubin,	creatine	kinase	and	alkaline	phosphatase),	 lipid	panel,	
haematology, urinalysis and electrocardiogram. In addition, at the re-
quest	of	several	European	countries,	measurements	of	serum	amyl-
ase and lipase were instituted after the study was initiated; therefore, 
not all subjects had baseline values. Renal function was assessed by 
measuring	 eGFR	 (MDRD	 formula13).	 A	 standard	 questionnaire	 was	
provided to subjects to collect hypoglycaemia information.
Potential patients with pancreatitis (events assessed by the investi-
gator as possibly being pancreatitis or events meeting prespecified event 
terms	suggestive	of	pancreatitis)	and	prespecified	hypersensitivity	AEs	
(anaphylactic	reaction,	angiooedema,	asthma-	bronchospasm,	erythema	
multiforme,	Stevens-	Johnson	syndrome,	toxic	epidermal	necrolysis,	and	
drug	rash	with	eosinophilia	and	systemic	symptoms)	were	evaluated	in	a	
blinded	manner	by	external	clinical	adjudication	committees.
2.6 | Population pharmacokinetics
Population	 pharmacokinetics	 (PK)	 sampling	 was	 performed	 at	 Day	
1	 (predose),	Visit	 5/Week	6	 (planned	 time	point	2	hours	postdose),	
Visit	6/Week	12	(nominal	planned	time	point	1-	2	days	postdose),	Visit	
7/Week	18	(planned	time	point	predose	trough)	and	Visit	9/Week	30	
(planned	time	point	3-	5	days	postdose).
2.7 | Statistical methods
For efficacy analyses, the primary population included all randomised 
subjects who received at least one dose of study treatment and had 
a	baseline	or	a	postrandomisation	measurement.	Data	acquired	after	
the initiation of rescue therapy was treated as missing to avoid the 
confounding influence of rescue therapy.
Analysis	of	the	primary	efficacy	end-	point	 (change	from	baseline	
in	HbA1c)	used	a	 longitudinal	data	analysis	 (LDA)	model14 including 
terms for treatment, RI stratum, baseline treatment with insulin stra-
tum, time, the interaction of time by treatment, the interaction of time 
by RI stratum and the interaction of time by baseline treatment with 
insulin stratum, with a constraint that true mean at baseline is common 
to	all	treatment	groups	(which	is	valid	as	a	result	of	randomisation).	The	
primary hypothesis regarding the superiority of omarigliptin compared 
with	placebo	in	decreasing	HbA1c	was	assessed	using	the	estimated	
treatment	difference	 from	 the	LDA	model.	Change	 from	baseline	 in	
FPG	was	analysed	using	the	same	LDA	model,	substituting	the	appro-
priate	baseline	efficacy	measurement	for	HbA1c.
For	the	analysis	of	percentages	of	 individuals	at	 the	HbA1c	goal	
of	<7.0%	at	Week	24,	 the	LDA	model	described	above	was	used	to	
impute	missing	HbA1c	data.	Ten	sets	of	imputations	of	each	missing	
value	were	constructed	from	the	LDA	model.	Observed	data	were	not	
imputed.	After	imputations,	all	subjects	were	categorised	as	at	or	not	
at	the	goal	at	Week	24.	The	estimated	proportions	of	subjects	at	the	
goal from the 10 imputed datasets were combined using standard 
multiple	imputation	techniques	proposed	by	Rubin15 to yield an over-
all estimate of response rate and associated variance for each group.
The estimated response rates and adjusted effective sample sizes 
were	used	 to	obtain	 the	confidence	 interval	 (CI)	 for	between-	group	
rate	difference	by	the	method	of	Miettinen	and	Nurminen16 stratified 
by RI stratum and baseline treatment with insulin stratum.
Efficacy	end-	points	at	Week	54	were	summarised.	No	between-	
group	comparisons	were	prespecified	or	intended	for	Week	54,	since	
treatments were not concurrently initiated, and the placebo group 
switched to glipizide was no longer the intact group randomised at the 
beginning of the trial. Statistical models and analysis populations for 
Week	54	were	analogous	to	those	at	Week	24.
For safety analyses, the population of all randomised subjects who 
received	at	least	one	dose	of	study	treatment	was	used.	All	safety	end-	
points were analysed for the time frame consisting of the Treatment 
Period	 +28	days.	 The	 primary	 safety	 analysis	 excluded	 data	 after	
rescue	to	avoid	the	confounding	effect	of	rescue	medication.	AEs	of	
symptomatic hypoglycaemia were prespecified as events of interest 
and point estimates with P-	values	and	95%	CI	for	between-	treatment	
differences in the percentages of subjects with symptomatic hypo-
glycaemia	events	were	calculated	using	the	method	of	Miettinen	and	
Nurminen,16 with RI stratum and baseline insulin stratum as stratifi-
cation factors. For body weight and eGFR, change from baseline was 
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analysed	using	the	LDA	method	described	above	for	HbA1c,	substitut-
ing	the	appropriate	baseline	value	for	the	HbA1c.
The	trial	targeted	the	enrolment	of	100	subjects	(50	subjects/arm)	
with	moderate	RI;	60	subjects	(30	subjects/arm)	with	severe	RI;	and	
50	 subjects	 (25	 subjects/arm)	with	 ESRD	 on	 dialysis.	 Subjects	with	
moderate	RI	were	to	be	enrolled	so	that	at	least	50%	of	subjects	had	
an	eGFR	from	≥30	to	≤45	mL/min/1.73	m2. Using a standard devia-
tion	 (SD)	of	1.0%	and	factoring	 for	expected	missing	data,	105	ran-
domised	subjects	per	treatment	group	was	calculated	to	provide	90%	
power	to	detect	a	true	difference	of	0.47%	in	the	mean	change	from	
baseline	in	HbA1c	(2-	sided	test,	α=0.05).
For the assessment of safety, two treatment periods are described 
below:	the	placebo-	controlled	period	(Phase	A)	and	the	combined	54-	
week	treatment	period	(Phase	A	and	B).
3  | RESULTS
3.1 | Patient disposition and characteristics
A	total	of	644	patients	were	screened	and	431	were	excluded	dur-
ing	 screening	 (Figure	S2).	 The	 most	 common	 reason	 for	 not	 being	
randomised	 was	 screen	 failure	 (404	 patients).	 Screen	 failure	 most	
commonly occurred because of not meeting the antihyperglycaemic 
therapy	and	HbA1c	requirements	or	meeting	exclusionary	laboratory	
values. The trial was initiated on 5 October 2012, the last subject visit 
during	Phase	A	of	the	study	occurred	on	22	June	2015	and	the	last	
subject	visit	during	Phase	B	was	on	19	January	2016.
Of	 the	 213	 subjects	 randomised	 (107	 in	 the	 omarigliptin	 group	
and	106	in	the	placebo	group),	195	(91.5%)	completed	study	Phase	A	
on	study	medication	and	170	(79.8%)	completed	Phase	B	(Figure	S2).	
Baseline demographics and efficacy parameters were generally bal-
anced	 between	 the	 randomised	 treatment	 groups	 (Table	1).	 The	
mean	age	was	65.2	years,	 approximately	62%	were	male;	 the	mean	
body	mass	index	was	30.1	kg/m2, and mean duration of diabetes was 
15 years.
3.2 | Efficacy results
3.2.1 | Phase A (24- week placebo- controlled period)
From	a	mean	baseline	in	HbA1c	of	8.4%	in	the	omarigliptin	group	and	
8.3%	in	the	placebo	group,	the	LS	mean	(95%	CI)	for	the	change	from	
baseline	at	Week	24	 in	HbA1c	was	−0.77%	 (−1.00	 to	−0.54)	 in	 the	
omarigliptin	group	and	−0.44%	(−0.67	to	−0.21)	in	the	placebo	group	
with	a	between-	group	difference	of	−0.33%	(−0.63	to	−0.02);	P=0.035	
(Table	2).	 The	 reduction	 in	HbA1c	 from	baseline	 in	 the	omarigliptin	
group	 was	 generally	 consistent	 across	 subgroups	 (baseline	 HbA1c,	
age,	 sex,	 BMI,	 race,	 ethnicity,	 duration	 of	 diabetes,	 geographi-
cal	 region,	 renal	 stratum	 and	 insulin	 at	 screening,	 data	 not	 shown).	
However,	there	was	a	smaller	between-	group	difference	in	HbA1c	in	
subjects	using	insulin	(Table	S1).
Treatment with omarigliptin led to comparable reductions in 
HbA1c	 from	 baseline	 across	 renal	 strata,	 but	 the	 between-	group	
differences across strata were affected by unusually large placebo re-
ductions	in	the	severe	RI	and	ESRD	strata	(Table	2).
The	estimated	percentage	(95%	CI)	of	subjects	at	the	HbA1c	tar-
get	of	<7.0%	was	27.2%	(19.1	to	37.1)	in	the	omarigliptin	group	and	
19.2%	(12.2	to	28.8)	in	the	placebo	group;	P=0.305.
The	LS	mean	(95%	CI)	change	from	baseline	at	Week	24	in	FPG	was	
−1.4	mmol/L	(−2.0	to	−0.8)	in	the	omarigliptin	group	and	−1.1	mmol/L	
(−1.8	to	−0.5)	in	the	placebo	group	with	a	between-	group	difference	
of	−0.2	mmol/L	(−0.9	to	0.5);	nominal	P=0.540	(Table	2).
A	post	 hoc	 analysis	was	performed	 in	 the	moderate	RI	 stratum,	
subdividing	 it	 into	 two	 subgroups:	 eGFR	 ≥45-	<60	mL/min/1.73	m2 
and	eGFR	≥30-	<45	mL/min/1.73	m2	(Table	S2).	Although	the	number	
of subjects in these subgroups was limited, there was no attenuation 
of efficacy observed in the omarigliptin group in these two subgroups. 
From	 a	 mean	 baseline	 HbA1c	 of	 8.6%	 in	 the	 eGFR	 ≥45-	<60	mL/
min/1.73	m2	subgroup,	the	mean	change	from	baseline	in	HbA1c	was	
−0.68%	(n=18)	and	from	a	mean	baseline	HbA1c	of	8.2%	in	the	eGFR	
≥30-	<45	mL/min/1.73	m2 subgroup, the mean change from baseline 
in	HbA1C	was	−0.72%	(n=35).
3.2.2 | Phase A and Phase B (54- week treatment 
period)
The	LS	means	 (95%	CIs)	 for	 the	changes	from	baseline	at	Week	54	
in	HbA1c	in	the	omarigliptin	group	and	placebo/glipizide	group	were	
−0.79%	 (−1.10 to −0.47)	and	−0.83%	 (−1.16	 to	−0.49),	 respectively	
TABLE  1 Baseline demographic, anthropometric and disease 
characteristics of study treatment groups
Omarigliptin N=107 Placebo N=106
Age,	years 65.9±9.4 64.5±9.7
Male,	n	(%) 68	(63.6) 63	(59.4)
Race,	n	(%)
White 59	(55.1) 63	(59.4)
Asian 37	(34.6) 38	(35.8)
Black 7	(6.5) 4	(3.8)
Multi-	racial 4	(3.7) 0	(0.0)
Native	Hawaiian	or	
other Pacific Islander
0	(0.0) 1	(0.9)
Ethnicity,	n	(%)
Not	Hispanic	or	Latino 95	(88.8) 96	(90.6)
Hispanic	or	Latino 10	(9.3) 8	(7.5)
Unknown 2	(1.9) 2	(1.9)
Body	weight,	kg 80.0±16.3 84.2±20.4
BMI,	kg/m2 29.5±4.5 30.7±6.8
HbA1c,	% 8.3±0.8 8.3±0.8
FPG,	mmol/L 9.5±2.8 9.5±2.3
Duration	of	T2DM,	years 14.9±8.2 15.1±8.7
Values	are	mean±SD	unless	otherwise	noted.	BMI,	body	mass	index;	FPG,	
fasting	plasma	glucose;	T2DM,	type	2	diabetes	mellitus.
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(Table	S3).	 The	 profile	 of	 change	 in	 HbA1c	 over	 time	 is	 shown	 in	
Figure	1A.	 Twenty-	four	 of	 the	 97	 subjects	 in	 the	 placebo/glipizide	
group who entered Phase B were treated with blinded glipizide; the 
other subjects in the placebo/glipizide group were on insulin and per 
protocol did not receive blinded glipizide. The average daily dose of 
blinded	 glipizide	 was	 3.85	mg/d.	 A	 subgroup	 analysis	 showed	 that	
treatment	with	omarigliptin	led	to	reductions	in	HbA1c	from	baseline	
at	Week	54	 in	all	 renal	strata	 in	subjects	who	were	or	were	not	on	
insulin	at	screening	(Table	S3).
The	LS	means	and	 the	95%	CIs	 for	 the	change	 from	baseline	at	
Week	 54	 in	 FPG	 in	 the	 omarigliptin	 group	 and	 placebo/glipizide	
group	 were	 −1.1	mmol/L	 (−2.0	 to	 −0.1)	 and	 −0.9	mmol/L	 (−1.9	 to	
0.1),	 respectively.	Change	 from	baseline	 in	FPG	over	 time	 is	 shown	
in Figure 1B.
The	 approximate	 percentage	 (95%	 CI)	 of	 subjects	 with	 HbA1c	
<7.0%	at	Week	54	was	31.1%	(22.2	to	41.8)	in	the	omarigliptin	group	
and	34.2%	(24.8	to	45.1)	in	the	placebo/glipizide	group.
3.3 | Safety results
3.3.1 | Phase A (24- week placebo- controlled period)
During	 the	 first	 24	weeks	 (Phase	 A)	 of	 the	 trial,	 the	 incidences	 of	
subjects	with	one	or	more	AEs,	drug-	related	AEs,	serious	AEs	(SAEs)	
and	discontinuations	due	to	AEs	were	similar	in	the	omarigliptin	and	
placebo	groups	 (Table	3).	One	subject	died	 in	each	treatment	group	
(one	fatal	SAE	of	acute	cardiac	failure	 in	the	omarigliptin	group	and	
one	fatal	SAE	of	cardiorespiratory	arrest	in	the	placebo	group).	There	
Parameter Omarigliptin N=106a Placebo N=106
HbA1c,	%
Full analysis set
Baseline 8.4±0.8 8.3±0.8
Week	24 7.5±1.1 7.9±1.1
Change from baselineb −0.77	(−1.00	to	−0.54) −0.44	(−0.67	to	−0.21)
Change vs. placeboc −0.33	(−0.63	to	−0.02)d —
Moderate	renal	impairment,	not	on	dialysis
	(eGFR	≥30	to	<60	mL/
min/1.73	m2)
n=53 n=61
Baseline 8.3±0.8 8.4±0.8
Week	24 7.6±0.8 8.1±1.1
Change from baselineb −0.68	(−0.95	to	−0.42) −0.06	(−0.31	to	0.18)
Change vs. placeboc −0.62	(−0.97	to	−0.26) —
Severe renal impairment, not on dialysis
	(eGFR	<30	mL/min/1.73	m2) n=32 n=22
Baseline 8.5±0.8 8.3±0.7
Week	24 7.5±1.4 7.4±1.1
Change from baselineb −0.80	(−1.33	to	−0.27) −0.88	(−1.50	to	−0.27)
Change vs. placeboc 0.09	(−0.7	to	0.87) —
ESRD on dialysis n=21 n=23
Baseline 8.2±0.9 8.3±0.8
Week	24 7.4±1.3 7.6±1.0
Change from baselineb −0.75	(−1.31	to	−0.20) −0.64	(−1.16	to	−0.13)
Change vs. placeboc −0.11	(−0.86	to	0.64) —
FPG,	mmol/L
Full analysis set
Baseline 9.4±2.8 9.5±2.3
Week	24 7.9±2.4 8.1±2.3
Change from baselineb −1.4	(−2.0	to	−0.8) −1.1	(−1.8	to	−0.5)
Change vs. placeboc −0.2	(−0.9	to	0.5) —
Values	are	mean±SD	unless	otherwise	noted.	To	convert	mmol/L	to	mg/dL	multiply	by	18.	aOne subject in 
the	omarigliptin	arm	discontinued	study	medication	before	taking	the	first	dose	and	is	therefore	not	included	
in any analysis population. bLeast	squares	(LS)	mean	(95%	CI).	cDifference	in	LS	means	(95%	CI).	dP=0.035.	
eGFR,	estimated	glomerular	filtration	rate;	ESRD,	end-	stage	renal	disease;	FPG,	fasting	plasma	glucose.
TABLE 2 Efficacy	end-	points	at	Week	24
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were	no	clinically	meaningful	between-	group	differences	 in	 specific	
AEs	in	any	System	Organ	Class	(SOC,	based	on	Medical	Dictionary	for	
Regulatory	Activities	Version	17.117;	data	not	shown).
The	percentage	of	subjects	reporting	one	or	more	AEs	of	symptom-
atic	hypoglycaemia	was	17.0%	(18/106)	in	the	omarigliptin	and	15.1%	
(16/106)	in	the	placebo	groups;	P=0.709.	All	subjects	experiencing	an	
AE	of	symptomatic	hypoglycaemia	were	on	insulin	therapy	at	screen-
ing	(Table	4).	The	incidences	of	severe	hypoglycaemia	(any	episode	of	
symptomatic	hypoglycaemia	that	required	medical	or	non-	medical	as-
sistance)	were	5.7%	(6/106)	in	the	omarigliptin	and	7.5%	(8/106)	in	the	
placebo	groups;	1.9%	of	subjects	(2/106)	in	the	omarigliptin	and	2.8%	
of	subjects	(3/106)	in	the	placebo	groups	required	medical	assistance.
The	LS	mean	(95%	CI)	change	from	baseline	in	eGFR	was	−0.5	mL/
min/1.73	m2	 (−2.1	 to	 1.2)	 in	 the	 omarigliptin	 group	 and	 −0.0	mL/
min/1.73	m2	(−1.8	to	1.7)	in	the	placebo	group	(between-	group	differ-
ence	of	−0.4	mL/min/1.73	m2	 [−2.7	to	1.9];	P=0.720).	During	Phase	
A,	 3.8%	 of	 subjects	 (4/106)	 in	 the	 omarigliptin	 group	 and	 5.7%	 of	
subjects	(6/106)	in	the	placebo	group	in	the	moderate	RI	stratum	had	
worsening of renal function defined as two consecutive eGFR values 
<30	mL/min/1.73	m2 on different days during the treatment period.
The	LS	mean	(95%	CI)	change	from	baseline	in	body	weight	was	
−0.1	kg	(−0.6	to	0.5)	in	the	omarigliptin	group	and	−0.3	kg	(−0.8	to	0.2)	
in the placebo group; P=0.477.
3.3.2 | Phase A and Phase B (54- week treatment 
period)
Over	 the	 54-	week	 treatment	 period	 (Phase	 A	 and	 Phase	 B),	 there	
were no notable differences between the omarigliptin and placebo/
glipizide	groups	in	summary	AE	measures,	including	the	percentage	of	
subjects	with	one	or	more	AEs,	drug-	related	AEs,	SAEs,	and	discon-
tinuations	due	to	AEs	 (Table	3).	There	were	no	clinically	meaningful	
differences	in	overall	AEs	by	SOC	or	of	any	specific	AE	within	an	SOC	
(data	not	shown).	In	the	renal	disorders	SOC,	none	of	the	AEs	in	the	
omarigliptin group led to the discontinuation of study medication or 
were considered by the investigator to be related to study drug.
The	percentage	of	subjects	 reporting	one	or	more	AEs	of	symp-
tomatic	 hypoglycaemia	was	22.6%	 (24/106)	 in	 the	omarigliptin	 and	
20.8%	(22/106)	in	the	placebo/glipizide	group;	P=0.915.	In	those	on	
insulin,	the	incidence	of	symptomatic	hypoglycaemia	was	32.9%	in	the	
omarigliptin	group	and	30.2%	in	the	placebo/glipizide	group	(Table	4).	
One	of	the	subjects	with	an	AE	of	symptomatic	hypoglycaemia	in	the	
omarigliptin	group	was	not	on	insulin	(2.8%),	while	three	subjects	not	
on	insulin	in	the	placebo/glipizide	group	had	at	least	one	AE	of	symp-
tomatic	hypoglycaemia	(7.0%),	one	of	which	was	severe.
The	LS	mean	(95%	CI)	change	from	baseline	in	eGFR	was	−2.0	mL/
min/1.73	m2	 (−4.0	 to	 −0.1)	 in	 the	 omarigliptin	 group	 and	 −2.3	mL/
min/1.73	m2	(−4.3	to	−0.2)	in	the	placebo	group.	During	Phase	A	and	
Phase	B,	11.3%	of	subjects	(6/53)	in	the	omarigliptin	group	and	14.8%	
of	subjects	(9/61)	in	the	placebo/glipizide	group	in	the	moderate	renal	
stratum had worsening renal function.
Both	at	 the	24-	week	 time	point	 (placebo-	controlled	period)	 and	
over	54	weeks,	omarigliptin	treatment	did	not	result	 in	any	clinically	
meaningful changes from baseline in safety laboratory measures or 
between-	group	 differences	 in	 percentage	 of	 subjects	who	met	 pre-
defined limits of change for safety laboratory measures, including liver 
tests and lipids. Similarly, there were no clinically meaningful changes 
from baseline in blood pressure, pulse rate or ECG parameters.
The	LS	mean	(95%	CI)	change	from	baseline	in	body	weight	was	
−0.6	kg	 (−2.1	 to	0.8)	 in	 the	omarigliptin	 group	and	−1.5	kg	 (−2.9	 to	
−0.0)	in	the	placebo	group.
Small increases from baseline in mean serum amylase were ob-
served	 in	 the	 overall	 population	 (combined	 strata)	 at	Week	 24	 and	
Week	 54	 in	 both	 treatment	 groups;	 the	 mean	 change	was	 slightly	
greater	 in	 the	 omarigliptin	 group	 at	Week	 24	 but	 not	 at	Week	 54.	
Mean	 baseline,	Week	 24	 and	Week	 54	 serum	 amylase	 levels	were	
within	normal	 laboratory	 range	 in	both	 treatment	groups	 (Table	S4).	
Small increases from baseline in mean serum lipase were observed in 
the	overall	population	 (combined	strata)	 in	the	omarigliptin	group	at	
Week	24	and	Week	54.	Mean	baseline	and	Week	54	values	of	serum	
F IGURE  1 Efficacy	measures	through	Week	54;	A)	change	from	
baseline	HbA1c	(%);	B)	change	from	baseline	fasting	plasma	glucose	
(mmol/L);	 omarigliptin;  placebo; based on a model with terms for 
treatment,	chronic	renal	impairment	(RI)	stratum,	baseline	treatment	
with insulin stratum, time, the interaction of time by treatment, 
the interaction of time by RI stratum, and the interaction of time 
by baseline treatment with insulin stratum with the restriction of a 
common baseline mean across treatment groups
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lipase were slightly above the laboratory upper limit of normal for both 
treatment	groups	(Table	S4).
There	 were	 no	 adjudication-	confirmed	 patients	 of	 prespecified	
hypersensitivity	or	pancreatitis	 (acute	or	 chronic)	 during	Phase	A	or	
Phase B of the trial.
3.4 | Population pharmacokinetics
Sparse	PK	data	 from	 this	 study	were	pooled	with	 the	PK	data	 from	
other	Phase	1,	Phase	2	and	Phase	3	 trials	 for	 an	 integrated	popula-
tion	PK	analysis.	 The	details	 of	 this	 analysis	will	 be	 the	 subject	of	 a	
separate	 publication.	 The	 population	 PK	 analysis,	 including	 PK	 data	
from this study, demonstrated that the 25 mg dose in subjects with 
moderate renal impairment and 12.5 mg dose in subjects with severe 
renal	 impairment	and	ESRD	achieved	omarigliptin	plasma	drug	expo-
sures	which	were	within	1.5	-	fold	the	exposure	of	25	mg	dose	in	a	nor-
mal	renal	function.	The	results	of	the	pooled	PK	analysis	showed	that	
plasma	exposures	with	omarigliptin	12.5	mg	and	25	mg	were	consist-
ent with those predicted from an earlier clinical pharmacology trial.18
4  | DISCUSSION
Omarigliptin	 has	 a	 long	 half-	life	 that	 supports	 once-	weekly	 dosing.	
The	long	half-	life	of	omarigliptin	is	because	of	its	limited	metabolism	
and low renal clearance. Because omarigliptin is eliminated primarily 
TABLE  3 Adverse	events	summary
Subjects, n (%)
Phase A Phase A + B
Omarigliptin N=106b Placebo N=106 Omarigliptin N=106 Placebo/glipizide N=106
With	one	or	more
AEs 70	(66.0) 74	(69.8) 82	(77.4) 83	(78.3)
Drug-	relateda	AEs 10	(9.4) 9	(8.5) 13	(12.3) 10	(9.4)
Serious	AEs 9	(8.5) 13	(12.3) 21	(19.8) 20	(18.9)
Serious	drug-	relateda	AEs 1	(0.9) 0	(0.0) 1	(0.9) 0	(0.0)
Who	died 1	(0.9) 1	(0.9) 2	(1.9) 3	(2.8)
Who	discontinued	due	to
An	AE 3	(2.8) 1	(0.9) 7	(6.6) 4	(3.8)
A	drug-	relateda	AE 1	(0.9) 1	(0.9) 2	(1.9) 1	(0.9)
A	serious	AE 1	(0.9) 0	(0.0) 3	(2.8) 3	(2.8)
A	serious	drug-	relateda	AE 0	(0.0) 0	(0.0) 0	(0.0) 0	(0.0)
aAssessed	by	the	investigator	to	be	related	to	the	drug.	bOne	subject	in	the	omarigliptin	arm	discontinued	study	medication	before	taking	the	first	dose	and	
is therefore not included in any analysis population.
TABLE  4 Adverse	events	of	hypoglycaemia
Subjects, n (%)
Phase A Phase A + B
Omarigliptin N=106 Placebo N=106 Omarigliptin N=106 Placebo/glipizide N=106
On insulin n=70 n=63 n=70 n=63
With	one	or	more	AE	of	
hypoglycaemia
22	(31.4) 19	(30.2) 28	(40.0) 22	(34.9)
Symptomatica 18	(25.7) 16	(25.4) 23	(32.9) 19	(30.2)
Severeb 	6	(8.6) 8	(12.7) 7	(10.0) 8	(12.7)
Asymptomaticc 11	(15.7) 6	(9.5) 14	(20.0) 12	(19.0)
Not	on	insulin n=36 n=43 n=36 n=43
With	one	or	more	AE	of	
hypoglycaemia
0	(0.0) 0	(0.0) 1	(2.8) 3	(7.0)
Symptomatica 0	(0.0) 0	(0.0) 1	(2.8) 3	(7.0)
Severeb 0	(0.0) 0	(0.0) 0	(0.0) 1	(2.3)
Asymptomaticc 0	(0.0) 0	(0.0) 0	(0.0) 0	(0.0)
aSymptomatic hypoglycaemia: episode with clinical symptoms attributed to hypoglycaemia, without regard to glucose level. bSevere hypoglycaemia: epi-
sode	that	required	assistance,	either	medical	or	non-	medical.	Episodes	with	a	markedly	depressed	level	of	consciousness,	a	loss	of	consciousness,	or	seizure	
were	classified	as	having	required	medical	assistance,	whether	or	not	medical	assistance	was	obtained.	 cAsymptomatic	hypoglycaemia:	glucose	values	
≤3.9	mmol/L	without	symptoms.
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by	the	kidney,	the	assessment	of	efficacy	and	safety	of	omarigliptin	in	
subjects with renal impairment is of particular interest.
In this study, in the overall population of subjects with renal im-
pairment,	 treatment	 with	 omarigliptin	 once	 weekly	 for	 24	weeks	
achieved	 a	 clinically	 meaningful	 reduction	 in	 HbA1c	 from	 baseline	
compared with placebo and the prespecified primary efficacy hypoth-
esis	for	HbA1c	in	the	placebo-	controlled	portion	of	the	trial	(Phase	A)	
was	met.	The	proportion	of	subjects	achieving	HbA1c	goals	of	<7.0%	
were numerically higher in the omarigliptin group than the placebo 
group, although the difference between the treatment groups was not 
significant.	Treatment	for	24	weeks	with	omarigliptin	compared	with	
placebo did not result in a significant reduction in FPG, the secondary 
glycaemic	end-	point.	The	lack	of	a	between-group	difference	in	FPG	
may	be	attributed	 to	a	decrease	 in	FPG	over	24	weeks	observed	 in	
the	placebo	group.	Notably,	the	initial	(at	Week	6)	between-	group	dif-
ference	in	FPG	was	substantial,	but	subsequently	FPG	in	the	placebo	
group decreased from baseline, narrowing the difference between 
groups.	The	decrease	in	the	placebo	group	was	unexpected,	and	could	
reflect a trial effect in that group, with greater compliance to diet and 
medication	(eg,	insulin).
In subgroups based on degree of RI, similar reductions from base-
line	in	HbA1c	were	observed	across	all	renal	strata	in	the	omarigliptin	
group;	however,	because	of	varying	degrees	of	reductions	in	HbA1c	in	
the	placebo	group,	smaller	between-	group	differences	 in	 the	severe	
RI and ESRD on dialysis subgroups were observed compared with the 
moderate RI subgroup. Subgroup results, which contain smaller num-
bers of subjects, should be viewed with caution since the study was 
not	designed	to	have	precision	to	examine	subgroup	effects.
Improvements in glycaemic control in subjects on placebo have 
been	attributed	 to	better	adherence	 to	diet	and	exercise	associated	
with	participation	in	a	clinical	trial,	although	this	explanation	is	unlikely	
to completely account for the magnitude of effect observed in this 
study	in	some	subgroups.	Overall,	63%	of	subjects	in	the	study	were	
on insulin therapy. The change from baseline with placebo was more 
prominent in subjects on insulin than those not on insulin, which raises 
the possibility that the trial effect reflected not only better adherence 
to	diet	and	exercise,	but	also	better	adherence	to	(or	adjustment	of)	
insulin therapy. Because subjects on insulin routinely monitor their 
finger-	stick	glucose,	adherence	to	insulin,	diet	and	exercise	may	be	in-
fluenced	by	knowledge	of	glucose	measurements,	leading	to	unequal	
trial effects in the two treatment arms.
It	is	unlikely	that	omarigliptin	has	a	different	therapeutic	effect	in	
subjects with severe RI and ESRD compared with those with moderate 
RI.	Based	on	the	properties	of	omarigliptin,	there	is	no	reason	to	ex-
pect	a	different	efficacy	profile	between	omarigliptin	and	other	DPP-	4	
inhibitors.	DPP-	4	inhibitors	are	effective	in	patients	with	chronic	renal	
impairment including in patients with varying degrees of RI, providing 
strong	 evidence	 that	 DPP-	4	 inhibition	 is	maintained	 irrespective	 of	
renal status.
There were no prespecified comparisons of the omarigliptin group 
with the placebo/glipizide group in Phase B, since the treatments (om-
arigliptin	 and	 glipizide)	were	 not	 concurrently	 initiated	 and	 subjects	
in the placebo/glipizide group at entry into Phase B were no longer 
the	intact	group	randomised	at	the	beginning	of	Phase	A.	The	reason	
for the use of glipizide in Phase B was to provide subjects who were 
randomised	to	placebo	in	Phase	A	and	who	were	not	on	insulin	with	
an	oral	AHA	treatment	under	blinded	conditions	to	avoid	inadequate	
glycaemic control during Phase B.
Treatment	with	 omarigliptin	 once	weekly	 resulted	 in	 reductions	
in	HbA1c	and	FPG	from	baseline	throughout	the	54-	week	treatment	
period	in	the	overall	study	population	(combined	renal	strata).	A	sub-
group analysis by renal stratum and insulin use at baseline showed 
that reductions were observed in all renal strata regardless of insulin 
use	at	baseline.	Given	the	known	efficacy	of	glipizide	in	patients	with	
RI,19,20	the	observation	of	similar	reductions	in	HbA1c	at	Week	54	in	
both	treatment	groups	supports	the	efficacy	of	omarigliptin	at	Week	
54	in	this	study	population.
No	notable	between-	group	differences	occurred	 in	 any	SOC	 in-
cluding the renal disorders SOC. Small mean decreases in eGFR were 
observed in both treatment groups. The percentage of subjects with 
worsening	 of	 renal	 function	 in	 both	 Phase	A	 and	B	was	 similar	 be-
tween treatment groups. The small changes in these renal parameters 
are consistent with progression of renal disease that might be antici-
pated in the study population.21 Thus, there were no findings to sug-
gest	that	omarigliptin	treatment	increases	the	risk	of	worsening	renal	
dysfunction in this study population with RI.
The	hypoglycaemia	profile	is	an	important	feature	of	any	AHA.	In	
this	 study,	 there	were	no	notable	between-	group	differences	 in	 the	
incidences of symptomatic, asymptomatic or severe hypoglycaemia. 
Consistent with the recognised increase in hypoglycaemia when 
DPP-	4	inhibitors	are	used	with	agents	that	are	associated	with	hypo-
glycaemia	(such	as	sulfonylureas	and	insulin)	almost	all	of	the	subjects	
experiencing	hypoglycaemia	in	this	study	were	using	insulin	concom-
itantly, while only one subject in the omarigliptin group and three in 
the	placebo/glipizide	group	not	on	insulin	had	an	AE	of	symptomatic	
hypoglycaemia.
The small changes from baseline in mean serum amylase and lipase 
did not appear to be clinically meaningful. There were no patients of 
adjudication-	confirmed	pancreatitis	in	either	treatment	group.
The	results	of	PK	analysis	were	consistent	with	previous	predictions	
that were used to support the selection of doses for this trial18 and 
lend	further	support	for	the	use	of	25	mg	once	weekly	in	subjects	with	
moderate	RI	and	the	use	of	12.5	mg	once	weekly	in	subjects	with	se-
vere	RI	and	ESRD	to	maintain	exposures	of	omarigliptin	similar	to	those	
observed in patients with normal renal function. Omarigliptin is highly 
membrane permeable and not secreted by renal transporters [unpub-
lished data]. These properties account for the reabsorption of a large 
fraction	of	the	filtered	omarigliptin	in	the	kidney,	which	is	demonstrated	
by the observation that the unbound renal clearance of omarigliptin 
at steady state is substantially below the average glomerular filtration 
rate. It is postulated that the reabsorption of omarigliptin in the tubules 
occurs passively along with sodium and water reabsorption.22
The	present	 trial	 conducted	 in	 subjects	with	T2DM	and	varying	
degrees	of	RI,	extends	our	understanding	of	omarigliptin	efficacy	and	
safety in this patient population. The safety profile of omarigliptin ob-
served in this trial is consistent with the safety profile of presently 
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marketed	daily	DPP-	4	inhibitors.	The	results	of	this	trial	support	the	
safety	of	omarigliptin	with	long-	term	use	in	subjects	with	RI	(moderate	
and	severe	RI	and	ESRD	on	dialysis).
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